Screener
Cytek Biosciences, Inc. CTKB Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053496
FAQ
- What is Cytek Biosciences, Inc.'s cash & equivalents?
- Cytek Biosciences, Inc. (CTKB) reported cash & equivalents of $73.85M in Q2 2026.
- How has Cytek Biosciences, Inc.'s cash & equivalents changed year-over-year?
- Cytek Biosciences, Inc.'s cash & equivalents decreased by 2.2% year-over-year, from $75.47M to $73.85M.
- What is the long-term trend for Cytek Biosciences, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Cytek Biosciences, Inc.'s cash & equivalents has grown at a -29.4% compound annual growth rate (CAGR), from $165.23M to $28.98M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Cytek Biosciences, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude